Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $30.00 price target on the stock.